PHE's Goldman in Fortune: Innovative Drugs Deserve Innovative Pricing

PHE cofounder Dana Goldman, along with coauthor David Agus, contribute a new commentary for Discussing the significance of Kymriah, the first gene therapy for cancer to achieve FDA approval, Goldman and Agus make the point that although the promise and pricing of the new drug is grabbing all the headlines, the accompanying risk sharing agreement between CMS and Novartis is even more significant.

To read the complete article, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.